|
| Status |
Public on Nov 28, 2022 |
| Title |
MCF7-AROE, ENZ, biol rep 2 |
| Sample type |
SRA |
| |
|
| Source name |
MCF7
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: MCF7
cell type: human breast cancer
genotype: AR overexpression
treatment: Enzalutamide
time: Day 2
|
| Treatment protocol |
MCF7-Tet cells were used to create AR low (no doxycycline) and AR high cells (doxycycline 800ng/ml). Doxycycline was added to cell culture media 1 day before drug treatments.
MCF7 parental and AROE cells were treated with DMSO or Enzalutamide (10µM) for 24 hours.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was extracted using the RNeasy Plus Mini kit (74134, QIAGEN) per manufacturer’s instructions.
Poly-A enriched RNA library prep and sequencing were done by Mayo Next Gen sequencing cores using illumina truseq2 kit.
|
| |
|
| Library strategy |
RNA-Seq |
| Library source |
transcriptomic |
| Library selection |
cDNA |
| Instrument model |
Illumina HiSeq 4000 |
| |
|
| Data processing |
Filtered reads were aligned to hg38 human reference genome using STAR with average mapping rate of 93%. Raw counts were then called by HTSeq excluding non-unique mapped reads.
Read count extraction and normalization were performed by EdgeR package using R software
Assembly: hg38
Supplementary files format and content: tab-delimited text files include raw counts for each Sample
|
| |
|
| Submission date |
Apr 07, 2022 |
| Last update date |
Nov 29, 2022 |
| Contact name |
Liewei Wang |
| E-mail(s) |
wang.liewei@mayo.edu
|
| Organization name |
Mayo Clinic
|
| Department |
Molecular Pharmacology and Experimental Therapeutics department
|
| Street address |
200 First Street SW
|
| City |
Rochester |
| State/province |
Minnesota |
| ZIP/Postal code |
55901 |
| Country |
USA |
| |
|
| Platform ID |
GPL20301 |
| Series (1) |
| GSE200435 |
Gene expression change after Enzalutamide treatment in MCF7 cells |
|
| Relations |
| BioSample |
SAMN27406258 |
| SRA |
SRX14779012 |
